<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>7859100</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">33551779</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">7859100</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.3389/fnhum.2020.616054</article-id></all-ids><extracted-table><table-id>T1</table-id><table-label>Table 1</table-label><table-caption>List of studies with their different measures of rsFC included in ALE analysis examining the effect of ECT in depression.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1</label><caption><p>List of studies with their different measures of rsFC included in ALE analysis examining the effect of ECT in depression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>ALFF based rsFC</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>fALFF based rsFC</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>ReHo based rsFC</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Seed based rsFC</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Seed taken</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>RSN/ROI to RSN/ ROI</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>RSN taken</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>ROI taken</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Other measures of rsFC</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Correction for multiple comparisons</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>rsFC measure/ROI used in ALE analysis</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Other studies included in ALE analysis of the respective rsFC measure/ROI</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Abbott et al. (<xref rid="B3" ref-type="bibr">2013</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">RSN to RSN</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>pDMN to dmPFC, L. dlPFC</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" rowspan="1" colspan="1">pDMN (PCC, Precuneus) with dmPFC</td><td valign="top" align="left" rowspan="1" colspan="1">Leaver et al., <xref rid="B56" ref-type="bibr">2016b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abbott et al. (<xref rid="B2" ref-type="bibr">2014b</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HC</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">R. HC to R. TL</td><td valign="top" align="left" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Liu et al. (<xref rid="B62" ref-type="bibr">2015</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">L. sgACC</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">ALFF</td><td valign="top" align="left" rowspan="1" colspan="1">Kong et al., <xref rid="B49" ref-type="bibr">2017</xref>; Bai et al., <xref rid="B9" ref-type="bibr">2018b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Argyelan et al. (<xref rid="B5" ref-type="bibr">2016</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">SCC(peak coordinate on R. side)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER (fALFF); FDR (sbFC)</td><td valign="top" align="left" rowspan="1" colspan="1">fALFF</td><td valign="top" align="left" rowspan="1" colspan="1">Qiu et al., <xref rid="B79" ref-type="bibr">2019</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Leaver et al. (<xref rid="B56" ref-type="bibr">2016b</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">RSNs to ROI</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>mdTh/ vBGN, pDMN, aDMN, vDMN, SAL, OFN, AMTN</italic></td><td valign="top" align="left" rowspan="1" colspan="1"><italic>dACC, PCC, R. a TL, Precuneus, mdTh</italic>,</td><td valign="top" align="left" rowspan="1" colspan="1">GTN</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" rowspan="1" colspan="1">pDMN (PCC, Precuneus) with dmPFC</td><td valign="top" align="left" rowspan="1" colspan="1">Abbott et al., <xref rid="B3" ref-type="bibr">2013</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Qiu et al. (<xref rid="B80" ref-type="bibr">2016</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">ReHo</td><td valign="top" align="left" rowspan="1" colspan="1">Kong et al., <xref rid="B49" ref-type="bibr">2017</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Kong et al. (<xref rid="B49" ref-type="bibr">2017</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">ALFF <break/> ReHo</td><td valign="top" align="left" rowspan="1" colspan="1">Liu et al., <xref rid="B62" ref-type="bibr">2015</xref>; Qiu et al., <xref rid="B80" ref-type="bibr">2016</xref>; Bai et al., <xref rid="B9" ref-type="bibr">2018b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bai et al. (<xref rid="B9" ref-type="bibr">2018b</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>dmPFC</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">ALFF <break/> Seed (dmPFC) to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">Liu et al., <xref rid="B62" ref-type="bibr">2015</xref>; Qiu et al., <xref rid="B80" ref-type="bibr">2016</xref>; Kong et al., <xref rid="B49" ref-type="bibr">2017</xref>; Wang J. et al., <xref rid="B111" ref-type="bibr">2020</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Qiu et al. (<xref rid="B79" ref-type="bibr">2019</xref>)</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">fALFF</td><td valign="top" align="left" rowspan="1" colspan="1">Argyelan et al., <xref rid="B5" ref-type="bibr">2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang L. et al. (<xref rid="B115" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>R. aInsula (v)</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">Seed [R. aInsula (v)] to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">Zhang et al., <xref rid="B127" ref-type="bibr">2020</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Takamiya et al. (<xref rid="B101" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>R. HC, L. HC</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" rowspan="1" colspan="1">Seed (R. HC) to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang J. et al. (<xref rid="B111" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>L. AG, dmPFC</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FcHo</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">Seed (dmPFC) to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">Bai et al., <xref rid="B9" ref-type="bibr">2018b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Zhang et al. (<xref rid="B127" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>R. &amp; L. aInsula (v)</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">Seed [R. aInsula (v)] to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">Wang L. et al., <xref rid="B115" ref-type="bibr">2020</xref></td></tr></tbody></table><table-wrap-foot><p><italic>aDMN, anterior DMN; AMTN, Anteromedial Temporal network; mdTh, medio dorsal thalamus; OFN, Orbitofrontal network; pDMN, posterior DMN; SCC, Subcallosal cingulate cortex; SAL, Salience network; vBGN, ventral basal ganglia network; aTL, anterior Temporal lobe; GTN, Graph Theory and Network analysis; FcHo, Functional connectivity Homogeneity; FDR, False Discovery Rate; FWER, Family-wise Error Rate</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">List of studies with their different measures of rsFC included in ALE analysis examining the effect of ECT in depression.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">References</th><th valign="top" align="left">ALFF based rsFC</th><th valign="top" align="left">fALFF based rsFC</th><th valign="top" align="left">ReHo based rsFC</th><th valign="top" align="left">Seed based rsFC</th><th valign="top" align="left">Seed taken</th><th valign="top" align="left">RSN/ROI to RSN/ ROI</th><th valign="top" align="left">RSN taken</th><th valign="top" align="left">ROI taken</th><th valign="top" align="left">Other measures of rsFC</th><th valign="top" align="left">Correction for multiple comparisons</th><th valign="top" align="left">rsFC measure/ROI used in ALE analysis</th><th valign="top" align="left">Other studies included in ALE analysis of the respective rsFC measure/ROI</th></tr></thead><tbody><tr><td valign="top" align="left">Abbott et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">RSN to RSN</td><td valign="top" align="left">pDMN to dmPFC, L. dlPFC</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FDR</td><td valign="top" align="left">pDMN (PCC, Precuneus) with dmPFC</td><td valign="top" align="left">Leaver et al., ???</td></tr><tr><td valign="top" align="left">Abbott et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">HC</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">R. HC to R. TL</td><td valign="top" align="left">None</td></tr><tr><td valign="top" align="left">Liu et al. (???)</td><td valign="top" align="left">Yes</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">L. sgACC</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">ALFF</td><td valign="top" align="left">Kong et al., ???; Bai et al., ???</td></tr><tr><td valign="top" align="left">Argyelan et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">SCC(peak coordinate on R. side)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER (fALFF); FDR (sbFC)</td><td valign="top" align="left">fALFF</td><td valign="top" align="left">Qiu et al., ???</td></tr><tr><td valign="top" align="left">Leaver et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">RSNs to ROI</td><td valign="top" align="left">mdTh/ vBGN, pDMN, aDMN, vDMN, SAL, OFN, AMTN</td><td valign="top" align="left">dACC, PCC, R. a TL, Precuneus, mdTh,</td><td valign="top" align="left">GTN</td><td valign="top" align="left">FDR</td><td valign="top" align="left">pDMN (PCC, Precuneus) with dmPFC</td><td valign="top" align="left">Abbott et al., ???</td></tr><tr><td valign="top" align="left">Qiu et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">ReHo</td><td valign="top" align="left">Kong et al., ???</td></tr><tr><td valign="top" align="left">Kong et al. (???)</td><td valign="top" align="left">Yes</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">ALFF  ReHo</td><td valign="top" align="left">Liu et al., ???; Qiu et al., ???; Bai et al., ???</td></tr><tr><td valign="top" align="left">Bai et al. (???)</td><td valign="top" align="left">Yes</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">dmPFC</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">ALFF  Seed (dmPFC) to voxel</td><td valign="top" align="left">Liu et al., ???; Qiu et al., ???; Kong et al., ???; Wang J. et al., ???</td></tr><tr><td valign="top" align="left">Qiu et al. (???)</td><td/><td valign="top" align="left">Yes</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">fALFF</td><td valign="top" align="left">Argyelan et al., ???</td></tr><tr><td valign="top" align="left">Wang L. et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">R. aInsula (v)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">Seed [R. aInsula (v)] to voxel</td><td valign="top" align="left">Zhang et al., ???</td></tr><tr><td valign="top" align="left">Takamiya et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">R. HC, L. HC</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FDR</td><td valign="top" align="left">Seed (R. HC) to voxel</td><td valign="top" align="left">None</td></tr><tr><td valign="top" align="left">Wang J. et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">L. AG, dmPFC</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FcHo</td><td valign="top" align="left">FWER</td><td valign="top" align="left">Seed (dmPFC) to voxel</td><td valign="top" align="left">Bai et al., ???</td></tr><tr><td valign="top" align="left">Zhang et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">Yes</td><td valign="top" align="left">R. &amp; L. aInsula (v)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">Seed [R. aInsula (v)] to voxel</td><td valign="top" align="left">Wang L. et al., ???</td></tr></tbody></table></div>aDMN, anterior DMN; AMTN, Anteromedial Temporal network; mdTh, medio dorsal thalamus; OFN, Orbitofrontal network; pDMN, posterior DMN; SCC, Subcallosal cingulate cortex; SAL, Salience network; vBGN, ventral basal ganglia network; aTL, anterior Temporal lobe; GTN, Graph Theory and Network analysis; FcHo, Functional connectivity Homogeneity; FDR, False Discovery Rate; FWER, Family-wise Error Rate.</transformed-table></extracted-table><extracted-table><table-id>T2</table-id><table-label>Table 2</table-label><table-caption>List of studies with their different measures of rsFC excluded from ALE analysis examining the effect of ECT in depression and the reasons for exclusion.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T2" position="float"><label>Table 2</label><caption><p>List of studies with their different measures of rsFC excluded from ALE analysis examining the effect of ECT in depression and the reasons for exclusion.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Seed based rsFC</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Seed taken</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>RSN/ROI to RSN/ ROI rsFC</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>RSN taken</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>ROI taken</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Other measures of rsFC</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Correction for multiple comparisons</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Reason for exclusion from ALE analysis</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Beall et al. (<xref rid="B10" ref-type="bibr">2012</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">ROI to ROI</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>B/L ACC to OFC, Caudate</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Bonferroni</td><td valign="top" align="left" rowspan="1" colspan="1">No other study has matching ROI to ROI in result, Coordinates information NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Perrin et al. (<xref rid="B73" ref-type="bibr">2012</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">weighted FC for voxel to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used same measure of rsFC analysis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wei et al. (<xref rid="B120" ref-type="bibr">2014</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">VMHC for voxel to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used same measure of rsFC analysis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cano et al. (<xref rid="B21" ref-type="bibr">2016</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>R. cm/ sfAmyg</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used same seed for Seed-voxel rsFC analysis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Leaver et al. (<xref rid="B55" ref-type="bibr">2016a</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">RSN to ROI</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>aDMN &amp; vDMN to VS</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study has matching RSN to ROI in result</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mulders et al. (<xref rid="B68" ref-type="bibr">2016</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Variance ratio of FC within DMN mask for voxel to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used same measure of rsFC analysis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang et al. (<xref rid="B112" ref-type="bibr">2017</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>L. sfAmyg</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used same seed for Seed-voxel rsFC analysis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bai et al. (<xref rid="B8" ref-type="bibr">2018a</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>L. aHC, L. midHC</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used same seed for Seed-voxel rsFC analysis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang et al. (<xref rid="B113" ref-type="bibr">2018a</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">RSN to RSN, ROI to ROI</td><td valign="top" align="left" rowspan="1" colspan="1">Details in Table 5</td><td valign="top" align="left" rowspan="1" colspan="1">Details in Table 5</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Bonferroni</td><td valign="top" align="left" rowspan="1" colspan="1">No other study has matching RSN/ROI in result, Coordinates information NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang et al. (<xref rid="B114" ref-type="bibr">2018b</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>R. supTG</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FCD</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used same measure of rsFC or used same seed for Seed-voxel rsFC analysis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wei et al. (<xref rid="B118" ref-type="bibr">2018</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Person's correlation of FC for voxel to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used same measure of rsFC analysis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Li et al. (<xref rid="B60" ref-type="bibr">2019</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">gFCD</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used same measure of rsFC analysis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sinha et al. (<xref rid="B94" ref-type="bibr">2019</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">GTN</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" rowspan="1" colspan="1">GTN is not analyzed with ALE</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Leaver et al. (<xref rid="B57" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">GTN within HC</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" rowspan="1" colspan="1">GTN is not analyzed with ALE</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Qi et al. (<xref rid="B78" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">GMV (sMRI) + fALFF (rsfMRI)</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" rowspan="1" colspan="1">Guidelines for combining different modality of MRI in meta-analysis: NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sun et al. (<xref rid="B99" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">ROI to ROI</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Details in Table 5</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" rowspan="1" colspan="1">No other study has matching ROI to ROI in result, Coordinates information NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wei et al. (<xref rid="B119" ref-type="bibr">2020b</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes (within cerebellum)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>L. sgACC</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used similar mask</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wei et al. (<xref rid="B117" ref-type="bibr">2020a</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Within Thalamus</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Parietal Cortex, L. Pulvinar</italic></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" rowspan="1" colspan="1">No other study used same seed for Seed-voxel rsFC analysis</td></tr></tbody></table><table-wrap-foot><p><italic>ACC, Anterior Cingulate Cortex; OFC, Orbito Frontal Cortex; aDMN, anterior DMN; cm/sfAmyg, centromedian/superficial amygdala; midHC, middle hippocampus; supTG, superior temporal gyrus; vDMN, ventral DMN; VMHC, Voxel-Mirrored Homotopic Connectivity; VS, Ventral striatum; sgACC, subgenual Anterior Cingulate Cortex; gFCD, global Functional Connectivity Density; FDR, False Discovery Rate; FWER, Family-wise Error Rate</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">List of studies with their different measures of rsFC excluded from ALE analysis examining the effect of ECT in depression and the reasons for exclusion.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">References</th><th valign="top" align="left">Seed based rsFC</th><th valign="top" align="left">Seed taken</th><th valign="top" align="left">RSN/ROI to RSN/ ROI rsFC</th><th valign="top" align="left">RSN taken</th><th valign="top" align="left">ROI taken</th><th valign="top" align="left">Other measures of rsFC</th><th valign="top" align="left">Correction for multiple comparisons</th><th valign="top" align="left">Reason for exclusion from ALE analysis</th></tr></thead><tbody><tr><td valign="top" align="left">Beall et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">ROI to ROI</td><td valign="top" align="left">-</td><td valign="top" align="left">B/L ACC to OFC, Caudate</td><td valign="top" align="left">-</td><td valign="top" align="left">Bonferroni</td><td valign="top" align="left">No other study has matching ROI to ROI in result, Coordinates information NA</td></tr><tr><td valign="top" align="left">Perrin et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">weighted FC for voxel to voxel</td><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study used same measure of rsFC analysis</td></tr><tr><td valign="top" align="left">Wei et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">VMHC for voxel to voxel</td><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study used same measure of rsFC analysis</td></tr><tr><td valign="top" align="left">Cano et al. (???)</td><td valign="top" align="left">Yes</td><td valign="top" align="left">R. cm/ sfAmyg</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study used same seed for Seed-voxel rsFC analysis</td></tr><tr><td valign="top" align="left">Leaver et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">RSN to ROI</td><td/><td valign="top" align="left">aDMN &amp; vDMN to VS</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study has matching RSN to ROI in result</td></tr><tr><td valign="top" align="left">Mulders et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">Variance ratio of FC within DMN mask for voxel to voxel</td><td valign="top" align="left">FDR</td><td valign="top" align="left">No other study used same measure of rsFC analysis</td></tr><tr><td valign="top" align="left">Wang et al. (???)</td><td valign="top" align="left">Yes</td><td valign="top" align="left">L. sfAmyg</td><td/><td/><td/><td/><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study used same seed for Seed-voxel rsFC analysis</td></tr><tr><td valign="top" align="left">Bai et al. (???)</td><td valign="top" align="left">Yes</td><td valign="top" align="left">L. aHC, L. midHC</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study used same seed for Seed-voxel rsFC analysis</td></tr><tr><td valign="top" align="left">Wang et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">RSN to RSN, ROI to ROI</td><td valign="top" align="left">Details in Table 5</td><td valign="top" align="left">Details in Table 5</td><td valign="top" align="left">-</td><td valign="top" align="left">Bonferroni</td><td valign="top" align="left">No other study has matching RSN/ROI in result, Coordinates information NA</td></tr><tr><td valign="top" align="left">Wang et al. (???)</td><td valign="top" align="left">Yes</td><td valign="top" align="left">R. supTG</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FCD</td><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study used same measure of rsFC or used same seed for Seed-voxel rsFC analysis</td></tr><tr><td valign="top" align="left">Wei et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">Person's correlation of FC for voxel to voxel</td><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study used same measure of rsFC analysis</td></tr><tr><td valign="top" align="left">Li et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">gFCD</td><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study used same measure of rsFC analysis</td></tr><tr><td valign="top" align="left">Sinha et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">GTN</td><td valign="top" align="left">FDR</td><td valign="top" align="left">GTN is not analyzed with ALE</td></tr><tr><td valign="top" align="left">Leaver et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">GTN within HC</td><td valign="top" align="left">FDR</td><td valign="top" align="left">GTN is not analyzed with ALE</td></tr><tr><td valign="top" align="left">Qi et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">GMV (sMRI) + fALFF (rsfMRI)</td><td valign="top" align="left">FDR</td><td valign="top" align="left">Guidelines for combining different modality of MRI in meta-analysis: NA</td></tr><tr><td valign="top" align="left">Sun et al. (???)</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">ROI to ROI</td><td valign="top" align="left">-</td><td valign="top" align="left">Details in Table 5</td><td valign="top" align="left">-</td><td valign="top" align="left">FDR</td><td valign="top" align="left">No other study has matching ROI to ROI in result, Coordinates information NA</td></tr><tr><td valign="top" align="left">Wei et al. (???)</td><td valign="top" align="left">Yes (within cerebellum)</td><td valign="top" align="left">L. sgACC</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study used similar mask</td></tr><tr><td valign="top" align="left">Wei et al. (???)</td><td valign="top" align="left">Within Thalamus</td><td valign="top" align="left">Parietal Cortex, L. Pulvinar</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">FWER</td><td valign="top" align="left">No other study used same seed for Seed-voxel rsFC analysis</td></tr></tbody></table></div>ACC, Anterior Cingulate Cortex; OFC, Orbito Frontal Cortex; aDMN, anterior DMN; cm/sfAmyg, centromedian/superficial amygdala; midHC, middle hippocampus; supTG, superior temporal gyrus; vDMN, ventral DMN; VMHC, Voxel-Mirrored Homotopic Connectivity; VS, Ventral striatum; sgACC, subgenual Anterior Cingulate Cortex; gFCD, global Functional Connectivity Density; FDR, False Discovery Rate; FWER, Family-wise Error Rate.</transformed-table></extracted-table><extracted-table><table-id>T3</table-id><table-label>Table 3</table-label><table-caption>ALE results for studies using different measures of rsFC to study the effect of ECT in depression.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T3" position="float"><label>Table 3</label><caption><p>ALE results for studies using different measures of rsFC to study the effect of ECT in depression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Analysis</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>ECT</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>FDR/ FWER</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Brain region</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Cluster size (mm<sup><bold>3</bold></sup>)</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Peak MNI Coordinates (x, y, z)</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>ALE value</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold><italic>Z</italic> score</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold><italic>P</italic></bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">ALFF voxel wise</td><td valign="top" align="left" rowspan="1" colspan="1">Pre &gt; post</td><td valign="top" align="left" rowspan="1" colspan="1">FWER<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">L. CG, BA 32</td><td valign="top" align="left" rowspan="1" colspan="1">584</td><td valign="top" align="left" rowspan="1" colspan="1">−8, 24, 32</td><td valign="top" align="left" rowspan="1" colspan="1">0.011</td><td valign="top" align="left" rowspan="1" colspan="1">4.715</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ALFF voxel wise</td><td valign="top" align="left" rowspan="1" colspan="1">Post &gt; pre</td><td valign="top" align="left" rowspan="1" colspan="1">FWER<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td><td valign="top" align="left" colspan="6" rowspan="1">No significant clusters found</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ReHo voxel cluster</td><td valign="top" align="left" rowspan="1" colspan="1">Pre &gt; post</td><td valign="top" align="left" rowspan="1" colspan="1">FWER<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td><td valign="top" align="left" colspan="6" rowspan="1">No significant clusters found</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Network Based</td><td valign="top" align="left" rowspan="1" colspan="1">Post &gt; pre</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" rowspan="1" colspan="1">L. PCC, BA 31 R. PCC, BA 31</td><td valign="top" align="left" rowspan="1" colspan="1">600</td><td valign="top" align="left" rowspan="1" colspan="1">2, −56,32 8, −56, 24</td><td valign="top" align="left" rowspan="1" colspan="1">0.014 <break/> 0.013</td><td valign="top" align="left" rowspan="1" colspan="1">5.378 <break/> 5.165</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001 <break/> &lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">fALFF voxel to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">Pre &gt; post</td><td valign="top" align="left" rowspan="1" colspan="1">FWER</td><td valign="top" align="left" colspan="6" rowspan="1">No significant clusters found</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Seed (R. HC) to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">Post &gt; pre</td><td valign="top" align="left" rowspan="1" colspan="1">FWER<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">R. HC and R. PHG</td><td valign="top" align="left" rowspan="1" colspan="1">8864</td><td valign="top" align="left" rowspan="1" colspan="1">42, −22, −11</td><td valign="top" align="left" rowspan="1" colspan="1">0.008</td><td valign="top" align="left" rowspan="1" colspan="1">4.296</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Seed (R. HC) to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">Post &gt; pre</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" colspan="6" rowspan="1">No significant clusters found</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Seed (R. HC) to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">Pre &gt; post</td><td valign="top" align="left" rowspan="1" colspan="1">FDR</td><td valign="top" align="left" colspan="6" rowspan="1">No significant clusters found</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Seed (dmPFC) to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">Post &gt; pre</td><td valign="top" align="left" rowspan="1" colspan="1">FWER<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td><td valign="top" align="left" colspan="6" rowspan="1">No significant clusters found</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Seed (L. anterior Insula (ventral) to voxel</td><td valign="top" align="left" rowspan="1" colspan="1">Post &gt; pre</td><td valign="top" align="left" rowspan="1" colspan="1">FWER<xref ref-type="table-fn" rid="TN2"><sup>#</sup></xref></td><td valign="top" align="left" colspan="6" rowspan="1">No significant clusters found</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><label>*</label><p>Cluster level FWER;</p></fn><fn id="TN2"><label>#</label><p><italic>Voxel level FWER</italic>.</p></fn><p><italic>pre&gt; post, Greater before the ECT course; post&gt; pre, Greater after the ECT course/specified number of ECT sessions</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">ALE results for studies using different measures of rsFC to study the effect of ECT in depression.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">Analysis</th><th valign="top" align="left">ECT</th><th valign="top" align="left">FDR/ FWER</th><th valign="top" align="left">Brain region</th><th valign="top" align="left">Cluster size (mm3)</th><th valign="top" align="left">Peak MNI Coordinates (x, y, z)</th><th valign="top" align="left">ALE value</th><th valign="top" align="left">Z score</th><th valign="top" align="left">P</th></tr></thead><tbody><tr><td valign="top" align="left">ALFF voxel wise</td><td valign="top" align="left">Pre &gt; post</td><td valign="top" align="left">FWER???</td><td valign="top" align="left">L. CG, BA 32</td><td valign="top" align="left">584</td><td valign="top" align="left">−8, 24, 32</td><td valign="top" align="left">0.011</td><td valign="top" align="left">4.715</td><td valign="top" align="left">&lt;0.0001</td></tr><tr><td valign="top" align="left">ALFF voxel wise</td><td valign="top" align="left">Post &gt; pre</td><td valign="top" align="left">FWER???</td><td valign="top" align="left" colspan="6">No significant clusters found</td></tr><tr><td valign="top" align="left">ReHo voxel cluster</td><td valign="top" align="left">Pre &gt; post</td><td valign="top" align="left">FWER???</td><td valign="top" align="left" colspan="6">No significant clusters found</td></tr><tr><td valign="top" align="left">Network Based</td><td valign="top" align="left">Post &gt; pre</td><td valign="top" align="left">FDR</td><td valign="top" align="left">L. PCC, BA 31 R. PCC, BA 31</td><td valign="top" align="left">600</td><td valign="top" align="left">2, −56,32 8, −56, 24</td><td valign="top" align="left">0.014  0.013</td><td valign="top" align="left">5.378  5.165</td><td valign="top" align="left">&lt;0.001  &lt;0.001</td></tr><tr><td valign="top" align="left">fALFF voxel to voxel</td><td valign="top" align="left">Pre &gt; post</td><td valign="top" align="left">FWER</td><td valign="top" align="left" colspan="6">No significant clusters found</td></tr><tr><td valign="top" align="left">Seed (R. HC) to voxel</td><td valign="top" align="left">Post &gt; pre</td><td valign="top" align="left">FWER???</td><td valign="top" align="left">R. HC and R. PHG</td><td valign="top" align="left">8864</td><td valign="top" align="left">42, −22, −11</td><td valign="top" align="left">0.008</td><td valign="top" align="left">4.296</td><td valign="top" align="left">&lt;0.0001</td></tr><tr><td valign="top" align="left">Seed (R. HC) to voxel</td><td valign="top" align="left">Post &gt; pre</td><td valign="top" align="left">FDR</td><td valign="top" align="left" colspan="6">No significant clusters found</td></tr><tr><td valign="top" align="left">Seed (R. HC) to voxel</td><td valign="top" align="left">Pre &gt; post</td><td valign="top" align="left">FDR</td><td valign="top" align="left" colspan="6">No significant clusters found</td></tr><tr><td valign="top" align="left">Seed (dmPFC) to voxel</td><td valign="top" align="left">Post &gt; pre</td><td valign="top" align="left">FWER???</td><td valign="top" align="left" colspan="6">No significant clusters found</td></tr><tr><td valign="top" align="left">Seed (L. anterior Insula (ventral) to voxel</td><td valign="top" align="left">Post &gt; pre</td><td valign="top" align="left">FWER???</td><td valign="top" align="left" colspan="6">No significant clusters found</td></tr></tbody></table></div>*Cluster level FWER;#Voxel level FWER.pre&gt; post, Greater before the ECT course; post&gt; pre, Greater after the ECT course/specified number of ECT sessions.</transformed-table></extracted-table><extracted-table><table-id>T4</table-id><table-label>Table 4</table-label><table-caption>List of studies included in ALE analysis: clinical characteristics.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T4" position="float"><label>Table 4</label><caption><p>List of studies included in ALE analysis: clinical characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>1st Author (year)</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Sample characteristics</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>ECT characteristics</bold></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"><bold>•Total No., Age as Mean (SD), M: F <break/>•Disease details <break/>•Medication details (Class, Frequency in %) <break/>•Depression scale [Name: Pre ECT score Mean (SD), Post ECT score Mean (SD)]</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>•Pulse width, electrode placement, charge as times ST <break/>•Frequency of ECT session, session with Post ECT MRI- [Fixed no/ Last session as Mean (SD)] <break/>•Anesthetic (Name, Dose), Muscle relaxant (Name, Dose)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Abbott et al. (<xref rid="B3" ref-type="bibr">2013</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•12, 66.42 (9.78), 4:8 <break/>•Treatment resistance depression <break/>•AD (100%), AP (66.67%), MS (16.67%) <break/>•HAM-D: 34.56 (10.03), 2.89 (2.93) s</td><td valign="top" align="left" rowspan="1" colspan="1">•Brief, RUL (10) &amp; BT (2), 6 times (RUL) 2 times (BT) <break/>•3 times a week, &gt; 5 days (21.13 ± 13.90) <break/>•after Last session- 11.17 (3.33) <break/>•Methohexital, S Ch</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abbott et al. (<xref rid="B2" ref-type="bibr">2014b</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•19, 65.3 (8.0), 6:13 <break/>•UPD <break/>•AD (94.7%), AP (63.2%) <break/>•HAM-D: 32.6 (8.5), 8.4 (8.6)</td><td valign="top" align="left" rowspan="1" colspan="1">•<bold>NA</bold>, RUL (17) &amp; BT (2), 6 times (RUL) 2 times (BT) <break/>•3 times a week, &gt; 5 days (11 ± 8.4) after Last session- 11 (2.7) <break/>•Methohexital, S Ch</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Liu et al. (<xref rid="B62" ref-type="bibr">2015</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•23, 30.57 (9.43), 9:1z <break/>•UPD with Active suicidal risk <break/>•1 AD (68.2%), 2 AD (27.3%), AP (13.6%); SSRI (68.2%), SNRI (18.2%), NaSSA (36.4%) <break/>•HAM-D: 28.45 (4.93), 8.23 (4.55)</td><td valign="top" align="left" rowspan="1" colspan="1">•Brief, BT, 1.5–2 <break/>•1st 3 daily, then 3times a week, After 8th session <break/>•Propofol (1.5–2 mg/kg), S. Ch (0.5–1 mg/kg)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Argyelan et al. (<xref rid="B5" ref-type="bibr">2016</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•16, 48.5 (13. 6), 10:6 <break/>•Treatment resistance Depression (UPD = 13, BPD = 3) <break/>•All medications stopped except lorazepam <break/>•HAM-D: 28.2 (5.6), 10.3</td><td valign="top" align="left" rowspan="1" colspan="1">•Brief, BF, 1.5 <break/>•3 times a week, Last or 8th session- 6.4 (1.5) <break/>•Ketamine (1mg/kg)/ Methohexital 1mg/kg, S Ch. 1mg/kg</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Leaver et al. (<xref rid="B56" ref-type="bibr">2016b</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•30, 40.90 (12.45), 16:14 <break/>•Treatment resistance Depression (UPD = 24, BPD = 6) <break/>•Medications stopped 48–72 h prior to ECT course <break/>•HAM-D: 26.3 (5.8), 9.3 (5.5)</td><td valign="top" align="left" rowspan="1" colspan="1">•<bold>NA</bold>, RUL, 5 times <break/>•3 times a week, Last session- 10.04 (2.93) <break/>•Short acting anesthetic, <bold>NA</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Qiu et al. (<xref rid="B80" ref-type="bibr">2016</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•12, 34.4 (10.1), 4:8 <break/>•UPD <break/>•No medications <break/>•HAM-D: 35.9 ± 1.3, <bold>NA</bold></td><td valign="top" align="left" rowspan="1" colspan="1">•Brief, BT, <bold>NA</bold><break/>•1st 2weeks as 3times a week, then twice in 1 week; After 8th session <break/>•Thiopentone (3.0–5.0 mg/kg) and S. Ch (0.5–1.0 mg/kg)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Kong et al. (<xref rid="B49" ref-type="bibr">2017</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•13, 63.0 (4.9), 2:11 <break/>•Severe depressive episode without psychotic symptoms <break/>•1 AD (53.8%), 2 AD (46.2%), AP = 0, MS = 0; SSRI (92.3%), NaSSA (46.2%), SNRI (7.7%) <break/>•HAM-D: 38.6(3.3), 3.1(2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">•Brief, BF, <bold>NA</bold><break/>•3 times a week, Last session: 5.8(0.4) <break/>•Propofol, S. Ch</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bai et al. (<xref rid="B9" ref-type="bibr">2018b</xref>) (AMHU)</td><td valign="top" align="left" rowspan="1" colspan="1">•33, 35.97 (11.11), 15:18 <break/>•UPD = 25, BPD = 8 <break/>•SSRI (66.7%), SNRI (33.3%), NaSSA (6.1%), SARI (6.1%), AP (51.5%); AC (Stopped) <break/>•HAM-D: 22.42 (4.12), 5.24 (5.09)</td><td valign="top" align="left" rowspan="1" colspan="1">•<bold>NA</bold>, BF, <bold>NA</bold><break/>•3 times a week, Last session- 8.03 (1.91) <break/>•Propofol, S. Ch</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bai et al. (<xref rid="B9" ref-type="bibr">2018b</xref>) (USTC)</td><td valign="top" align="left" rowspan="1" colspan="1">•28, 35.25 (11.48), 6:22 <break/>•UPD = 23, BPD = 5 <break/>•SSRI (64.3%), SNRI (39.3%), NaSSA (28.6%), SARI (7.1%), AP (46.4%); AC (Stopped) <break/>•HAM-D: 21.54 (4.73), 8.36 (5.62)</td><td valign="top" align="left" rowspan="1" colspan="1">•<bold>NA</bold>, BF, <bold>NA</bold><break/>•3 times a week, Last session- 8.71 (1.80) <break/>•Propofol, S. Ch</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Qiu et al. (<xref rid="B79" ref-type="bibr">2019</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•24, 31.33 (10.79), 10:14 <break/>•Severe UPD <break/>•No medication in last 1 month and during the ECT course <break/>•HAM-D: 31.33 (4.55), 8.58 (5.62) s</td><td valign="top" align="left" rowspan="1" colspan="1">•Brief, BT, 1.5–2 times <break/>•1st 2 weeks as 3 times a week &amp; 2 times a week in 3rd week, After 8th session <break/>•Thiopentone 3–5 mg/kg, S Ch (0.5–1mg/kg)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang L. et al. (<xref rid="B115" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•23, 38.74 (11.02), 11:12 <break/>•UPD (Treatment resistance or for suicide) <break/>•1 AD (86.9%), 2 AD (13.1%), AP (39.1%); SSRI (82.3%), SNRI (21.7%), NaSSa/ SARI (8.6%) <break/>•HAM-D: 22.22 (4.74), 3.83 (2.15)</td><td valign="top" align="left" rowspan="1" colspan="1">•<bold>NA</bold>, BF, <bold>NA</bold><break/>•1st 3 daily, then 3 times a week; Last session- 7.36 (2) <break/>•Propofol, S Ch</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Takamiya et al. (<xref rid="B101" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•27, 67.5 (8.1), 8:19 <break/>•Depression with melancholic features (UPD = 22, BPD = 5) <break/>•AD (88.9%), AP (77.8%), MS (7.4%) <break/>•HAM-D: 32.0 (6.6), 6.0 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">•Brief, BL, <bold>NA</bold><break/>•2-3 times a week, Last session: 10.8 (1.8) <break/>•Propofol (1 mg/kg), S. Ch (0.5–1 mg/kg)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang J. et al. (<xref rid="B111" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•23, 38.74 (11.02), 11:12 <break/>•UPD (Treatment resistance/ suicide) <break/>•1 AD (86.9%), 2 AD (13.1%), AP (39.1%); SSRI (82.6%), SNRI (21.7%), NaSSA (4.34%) <break/>•HAM-D: 22.22 (4.74), 3.83 (2.15)</td><td valign="top" align="left" rowspan="1" colspan="1">•<bold>NA</bold>, BF, <bold>NA</bold><break/>•1st 3 daily, then 3 times a week; Last session: 7.26 (2) <break/>•Propofol, S. Ch</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Zhang et al. (<xref rid="B127" ref-type="bibr">2020</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">•45, 39.07(12.29), 11:34 <break/>•UPD = 36, BPD = 9 <break/>•SSRI (62.22%), SNRI (31.11%), AP (55.55%) <break/>•HAM-D: 24.11(5.63), <bold>NA</bold></td><td valign="top" align="left" rowspan="1" colspan="1">•Brief, BF, <bold>NA</bold><break/>•1st 3 daily, then 3times a week, Last Session: Range (6–12) <break/>•Propofol (0.2–0.5 mg/kg), S. Ch (0.5–1 mg/kg)</td></tr></tbody></table><table-wrap-foot><p><italic>AD, Antidepressants; AMHU, Anhui Mental Health Center as Study site; AP, Antipsychotics; BPD, Bipolar depression; BT, Bitemporal; HAM-D, Hamilton Depression Rating Scale; MS, Mood Stabilizer; NA, Information Not Available; NaSSA, Noradrenergic and specific serotonergic antidepressants; SARI, Serotonin antagonist and reuptake inhibitor; S. Ch, Succinylcholine; SD, Standard Deviation; SNRI, Serotonin-norepinephrine reuptake inhibitor; SSRI, Selective serotonin reuptake inhibitor; UPD, Unipolar depression; USTC, University of Science and Technology of China as Study site</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">List of studies included in ALE analysis: clinical characteristics.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">1st Author (year)</th><th valign="top" align="left">Sample characteristics</th><th valign="top" align="left">ECT characteristics</th></tr><tr><th/><th valign="top" align="left">•Total No., Age as Mean (SD), M: F •Disease details •Medication details (Class, Frequency in %) •Depression scale [Name: Pre ECT score Mean (SD), Post ECT score Mean (SD)]</th><th valign="top" align="left">•Pulse width, electrode placement, charge as times ST •Frequency of ECT session, session with Post ECT MRI- [Fixed no/ Last session as Mean (SD)] •Anesthetic (Name, Dose), Muscle relaxant (Name, Dose)</th></tr></thead><tbody><tr><td valign="top" align="left">Abbott et al. (???)</td><td valign="top" align="left">•12, 66.42 (9.78), 4:8 •Treatment resistance depression •AD (100%), AP (66.67%), MS (16.67%) •HAM-D: 34.56 (10.03), 2.89 (2.93) s</td><td valign="top" align="left">•Brief, RUL (10) &amp; BT (2), 6 times (RUL) 2 times (BT) •3 times a week, &gt; 5 days (21.13 ± 13.90) •after Last session- 11.17 (3.33) •Methohexital, S Ch</td></tr><tr><td valign="top" align="left">Abbott et al. (???)</td><td valign="top" align="left">•19, 65.3 (8.0), 6:13 •UPD •AD (94.7%), AP (63.2%) •HAM-D: 32.6 (8.5), 8.4 (8.6)</td><td valign="top" align="left">•NA, RUL (17) &amp; BT (2), 6 times (RUL) 2 times (BT) •3 times a week, &gt; 5 days (11 ± 8.4) after Last session- 11 (2.7) •Methohexital, S Ch</td></tr><tr><td valign="top" align="left">Liu et al. (???)</td><td valign="top" align="left">•23, 30.57 (9.43), 9:1z •UPD with Active suicidal risk •1 AD (68.2%), 2 AD (27.3%), AP (13.6%); SSRI (68.2%), SNRI (18.2%), NaSSA (36.4%) •HAM-D: 28.45 (4.93), 8.23 (4.55)</td><td valign="top" align="left">•Brief, BT, 1.5–2 •1st 3 daily, then 3times a week, After 8th session •Propofol (1.5–2 mg/kg), S. Ch (0.5–1 mg/kg)</td></tr><tr><td valign="top" align="left">Argyelan et al. (???)</td><td valign="top" align="left">•16, 48.5 (13. 6), 10:6 •Treatment resistance Depression (UPD = 13, BPD = 3) •All medications stopped except lorazepam •HAM-D: 28.2 (5.6), 10.3</td><td valign="top" align="left">•Brief, BF, 1.5 •3 times a week, Last or 8th session- 6.4 (1.5) •Ketamine (1mg/kg)/ Methohexital 1mg/kg, S Ch. 1mg/kg</td></tr><tr><td valign="top" align="left">Leaver et al. (???)</td><td valign="top" align="left">•30, 40.90 (12.45), 16:14 •Treatment resistance Depression (UPD = 24, BPD = 6) •Medications stopped 48–72 h prior to ECT course •HAM-D: 26.3 (5.8), 9.3 (5.5)</td><td valign="top" align="left">•NA, RUL, 5 times •3 times a week, Last session- 10.04 (2.93) •Short acting anesthetic, NA</td></tr><tr><td valign="top" align="left">Qiu et al. (???)</td><td valign="top" align="left">•12, 34.4 (10.1), 4:8 •UPD •No medications •HAM-D: 35.9 ± 1.3, NA</td><td valign="top" align="left">•Brief, BT, NA•1st 2weeks as 3times a week, then twice in 1 week; After 8th session •Thiopentone (3.0–5.0 mg/kg) and S. Ch (0.5–1.0 mg/kg)</td></tr><tr><td valign="top" align="left">Kong et al. (???)</td><td valign="top" align="left">•13, 63.0 (4.9), 2:11 •Severe depressive episode without psychotic symptoms •1 AD (53.8%), 2 AD (46.2%), AP = 0, MS = 0; SSRI (92.3%), NaSSA (46.2%), SNRI (7.7%) •HAM-D: 38.6(3.3), 3.1(2.9)</td><td valign="top" align="left">•Brief, BF, NA•3 times a week, Last session: 5.8(0.4) •Propofol, S. Ch</td></tr><tr><td valign="top" align="left">Bai et al. (???) (AMHU)</td><td valign="top" align="left">•33, 35.97 (11.11), 15:18 •UPD = 25, BPD = 8 •SSRI (66.7%), SNRI (33.3%), NaSSA (6.1%), SARI (6.1%), AP (51.5%); AC (Stopped) •HAM-D: 22.42 (4.12), 5.24 (5.09)</td><td valign="top" align="left">•NA, BF, NA•3 times a week, Last session- 8.03 (1.91) •Propofol, S. Ch</td></tr><tr><td valign="top" align="left">Bai et al. (???) (USTC)</td><td valign="top" align="left">•28, 35.25 (11.48), 6:22 •UPD = 23, BPD = 5 •SSRI (64.3%), SNRI (39.3%), NaSSA (28.6%), SARI (7.1%), AP (46.4%); AC (Stopped) •HAM-D: 21.54 (4.73), 8.36 (5.62)</td><td valign="top" align="left">•NA, BF, NA•3 times a week, Last session- 8.71 (1.80) •Propofol, S. Ch</td></tr><tr><td valign="top" align="left">Qiu et al. (???)</td><td valign="top" align="left">•24, 31.33 (10.79), 10:14 •Severe UPD •No medication in last 1 month and during the ECT course •HAM-D: 31.33 (4.55), 8.58 (5.62) s</td><td valign="top" align="left">•Brief, BT, 1.5–2 times •1st 2 weeks as 3 times a week &amp; 2 times a week in 3rd week, After 8th session •Thiopentone 3–5 mg/kg, S Ch (0.5–1mg/kg)</td></tr><tr><td valign="top" align="left">Wang L. et al. (???)</td><td valign="top" align="left">•23, 38.74 (11.02), 11:12 •UPD (Treatment resistance or for suicide) •1 AD (86.9%), 2 AD (13.1%), AP (39.1%); SSRI (82.3%), SNRI (21.7%), NaSSa/ SARI (8.6%) •HAM-D: 22.22 (4.74), 3.83 (2.15)</td><td valign="top" align="left">•NA, BF, NA•1st 3 daily, then 3 times a week; Last session- 7.36 (2) •Propofol, S Ch</td></tr><tr><td valign="top" align="left">Takamiya et al. (???)</td><td valign="top" align="left">•27, 67.5 (8.1), 8:19 •Depression with melancholic features (UPD = 22, BPD = 5) •AD (88.9%), AP (77.8%), MS (7.4%) •HAM-D: 32.0 (6.6), 6.0 (5.3)</td><td valign="top" align="left">•Brief, BL, NA•2-3 times a week, Last session: 10.8 (1.8) •Propofol (1 mg/kg), S. Ch (0.5–1 mg/kg)</td></tr><tr><td valign="top" align="left">Wang J. et al. (???)</td><td valign="top" align="left">•23, 38.74 (11.02), 11:12 •UPD (Treatment resistance/ suicide) •1 AD (86.9%), 2 AD (13.1%), AP (39.1%); SSRI (82.6%), SNRI (21.7%), NaSSA (4.34%) •HAM-D: 22.22 (4.74), 3.83 (2.15)</td><td valign="top" align="left">•NA, BF, NA•1st 3 daily, then 3 times a week; Last session: 7.26 (2) •Propofol, S. Ch</td></tr><tr><td valign="top" align="left">Zhang et al. (???)</td><td valign="top" align="left">•45, 39.07(12.29), 11:34 •UPD = 36, BPD = 9 •SSRI (62.22%), SNRI (31.11%), AP (55.55%) •HAM-D: 24.11(5.63), NA</td><td valign="top" align="left">•Brief, BF, NA•1st 3 daily, then 3times a week, Last Session: Range (6–12) •Propofol (0.2–0.5 mg/kg), S. Ch (0.5–1 mg/kg)</td></tr></tbody></table></div>AD, Antidepressants; AMHU, Anhui Mental Health Center as Study site; AP, Antipsychotics; BPD, Bipolar depression; BT, Bitemporal; HAM-D, Hamilton Depression Rating Scale; MS, Mood Stabilizer; NA, Information Not Available; NaSSA, Noradrenergic and specific serotonergic antidepressants; SARI, Serotonin antagonist and reuptake inhibitor; S. Ch, Succinylcholine; SD, Standard Deviation; SNRI, Serotonin-norepinephrine reuptake inhibitor; SSRI, Selective serotonin reuptake inhibitor; UPD, Unipolar depression; USTC, University of Science and Technology of China as Study site.</transformed-table></extracted-table></extracted-tables-set>